Novel heart failure therapy targeting transcriptional pathway in cardiomyocytes by a natural compound, curcumin

Circulation Journal

Volumn 74, Issue 6, 2010, Pages 1060-1066

  Morimoto, Tatsuya ^a   Sunagawa, Yoichi ^a   Fujita, Masatoshi ^b   Hasegawa, Koji ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Curcumin; Heart failure; Histone acetyltransferase; p300; Pharmacological therapy

Indexed keywords

ANACARDIC ACID; ATRIAL NATRIURETIC FACTOR; CURCUMIN; ENALAPRIL; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE ACETYLTRANSFERASE PCAF; HISTONE DEACETYLASE; MYOSIN HEAVY CHAIN BETA; TRANSCRIPTION FACTOR GATA 4;

ACETYLATION; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CELL NUCLEUS; CELL SIZE; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; ENZYME INHIBITION; ENZYME REGULATION; GENETIC TRANSCRIPTION; HEART FAILURE; HEART HYPERTROPHY; HEART MUSCLE CELL; HUMAN; INHIBITION KINETICS; NONHUMAN; PROTEIN BINDING; TRADITIONAL MEDICINE; CARDIOMEGALY; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; REVIEW;

ACETYLATION; CARDIOMEGALY; CURCUMIN; GENE EXPRESSION REGULATION; HEART FAILURE; HUMANS; MYOCYTES, CARDIAC; P300-CBP TRANSCRIPTION FACTORS;

EID: 77953490957     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.cj-09-1012     Document Type: Article

References (69)

1. Hosoda T, Kajstura J, Leri A, Anversa P. Mechanisms of myocardial regeneration. Circ J 2010; 74: 13-17.
2. Kaneda R, Fukuda K. MicroRNA is a new diagnostic and therapeutic target for cardiovascular disease and regenerative medicine. Circ J 2009; 73: 1397-1398.
3. Brownell JE, Zhou J, Ranalli T, Kobayashi R, Edmondson DG, Roth SY, et al. Tetrahymena histone acetyltransferase A: A homolog to yeast Gcn5p linking histone acetylation to gene activation. Cell 1996; 84: 843-851.
4. Whyte P, Williamson NM, Harlow E. Cellular targets for transformation by the adenovirus E1A proteins. Cell 1989; 56: 67-75.
5. Eckner R, Ewen ME, Newsome D, Gerdes M, DeCaprio JA, Lawrence JB, et al. Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor. Genes Dev 1994; 8: 869-884.
6. Chrivia JC, Kwok RP, Lamb N, Hagiwara M, Montminy MR, Goodman RH. Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature 1993; 365: 855-859.
7. Kwok RP, Lundblad JR, Chrivia JC, Richards JP, Bächinger HP, Brennan RG, et al. Nuclear protein CBP is a coactivator for the transcription factor CREB. Nature 1994; 370: 223-226.
8. Arany Z, Sellers WR, Livingston DM, Eckner R. E1A-associated p300 and CREB-associated CBP belong to a conserved family of coactivators. Cell 1994; 77: 799-800.
9. Roth SY, Denu JM, Allis CD. Histone acetyltransferases. Annu Rev Biochem 2001; 70: 81-120.
10. Sterner DE, Berger SL. Acetylation of histones and transcription-related factors. Microbiol Mol Biol Rev 2000; 64: 435-459.
11. Chan HM, La Thangue NB. p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J Cell Sci 2001; 114: 2363-2373.
12. Yang XJ, Ogryzko VV, Nishikawa J, Howard BH, Nakatani Y. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 1996; 382: 319-324.
13. Nagy L, Kao HY, Chakravarti D, Lin RJ, Hassig CA, Ayer DE, et al. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 1997; 89: 373-380.
14. Marmorstein R, Roth SY. Histone acetyltransferases: Function, structure, and catalysis. Curr Opin Genet Dev 2001; 11: 155-161.
15. De Rubertis F, Kadosh D, Henchoz S, Pauli D, Reuter G, Struhl K, et al. The histone deacetylase RPD3 counteracts genomic silencing in Drosophila and yeast. Nature 1996; 384: 589-591.
16. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997; 90: 595-606.
17. Boyes J, Byfield P, Nakatani Y, Ogryzko V. Regulation of activity of the transcription factor GATA-1 by acetylation. Nature 1998; 396: 594-598.
18. Hung HL, Lau J, Kim AY, Weiss MJ, Blobel GA. CREB-Binding protein acetylates hematopoietic transcription factor GATA-1 at functionally important sites. Mol Cell Biol 1999; 19: 3496-3505.
19. Martinez-Balbas MA, Bauer UM, Nielsen SJ, Brehm A, Kouzarides T. Regulation of E2F1 activity by acetylation. EMBO J 2000; 19: 662-671.
20. Liu L, Scolnick DM, Trievel RC, Zhang HB, Marmorstein R, Halazonetis TD, et al. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol Cell Biol 1999; 19: 1202-1209.
21. Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, et al. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev 1998; 12: 2831-2841.
22. Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyl-transferases. Cell 1996; 87: 953-959.
23. Hamamori Y, Sartorelli V, Ogryzko V, Puri PL, Wu HY, Wang JY, et al. Regulation of histone acetyltransferases p300 and PCAF by the bHLH protein twist and adenoviral oncoprotein E1A. Cell 1999; 96: 405-413.
24. Thompson PR, Wang D, Wang L, Fulco M, Pediconi N, Zhang D, et al. Regulation of the p300 HAT domain via a novel activation loop. Nat Struct Mol Biol 2004; 11: 308-315.
25. Roelfsema JH, White SJ, Ariyurek Y, Bartholdi D, Niedrist D, Papadia F, et al. Genetic heterogeneity in Rubinstein-Taybi syndrome: Mutations in both the CBP and EP300 genes cause disease. Am J Hum Genet 2005; 76: 572-580.
26. Ma H, Nguyen C, Lee KS, Kahn M. Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression. Oncogene 2005; 24: 3619-3631.
27. Kalkhoven E. CBP and p300: HATs for different occasions. Bio-chem Pharmacol 2004; 68: 1145-1155.
28. Roth JF, Shikama N, Henzen C, Desbaillets I, Lutz W, Marino S, et al. Differential role of p300 and CBP acetyltransferase during myo-genesis: p300 acts upstream of MyoD and Myf5. EMBO J 2003; 22: 5186-5196.
29. Yao TP, Oh SP, Fuchs M, Zhou ND, Ch'ng LE, Newsome D, et al. Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell 1998; 93: 361-372.
30. Bordoli L, Husser S, Luthi U, Netsch M, Osmani H, Eckner R. Functional analysis of the p300 acetyltransferase domain: The PHD finger of p300 but not of CBP is dispensable for enzymatic activity. Nucleic Acids Res 2001; 29: 4462-4471.
31. Shikama N, Lutz W, Kretzschmar R, Sauter N, Roth JF, Marino S, et al. Essential function of p300 acetyltransferase activity in heart, lung and small intestine formation. EMBO J 2003; 22: 5175-5185.
32. Tanaka Y, Naruse I, Hongo T, Xu M, Nakahata T, Maekawa T, et al. Extensive brain hemorrhage and embryonic lethality in a mouse null mutant of CREB-binding protein. Mech Dev 2000; 95: 133-145.
33. Morimoto T, Hasegawa K, Kaburagi S, Kakita T, Wada H, Yanazume T, et al. Phosphorylation of GATA-4 is involved in alpha 1-adrenergic agonist-responsive transcription of the endothe-lin-1 gene in cardiac myocytes. J Biol Chem 2000; 275: 13721-13726.
34. Yanazume T, Hasegawa K, Morimoto T, Kawamura T, Wada H, Matsumori A, et al. Cardiac p300 is involved in myocyte growth with decompensated heart failure. Mol Cell Biol 2003; 23: 3593-3606.
35. Kolodziejczyk SM, Wang L, Balazsi K, DeRepentigny Y, Kothary R, Megeney LA. MEF2 is upregulated during cardiac hypertrophy and is required for normal post-natal growth of the myocardium. Curr Biol 1999; 9: 1203-1206.
36. Paradis P, MacLellan WR, Belaguli NS, Schwartz RJ, Schneider MD. Serum response factor mediates AP-1-dependent induction of the skeletal alpha-actin promoter in ventricular myocytes. J Biol Chem 1996; 271: 10827-10833.
37. Dai YS, Cserjesi P, Markham BE, Molkentin JD. The transcription factors GATA4 and dHAND physically interact to synergistically activate cardiac gene expression through a p300-dependent mechanism. J Biol Chem 2002; 277: 24390-24398.
38. Hasegawa K, Lee SJ, Jobe SM, Markham BE, Kitsis RN. cis-Acting sequences that mediate induction of beta-myosin heavy chain gene expression during left ventricular hypertrophy due to aortic constriction. Circulation 1997; 96: 3943-3953.
39. Morimoto T, Hasegawa K, Kaburagi S, Kakita T, Masutani H, Kitsis RN, et al. GATA-5 is involved in leukemia inhibitory factor-responsive transcription of the beta-myosin heavy chain gene in cardiac myocytes. J Biol Chem 1999; 274: 12811-12818.
40. Chang S, McKinsey TA, Zhang CL, Richardson JA, Hill JA, Olson EN. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol 2004; 24: 8467-8476.
41. Davis FJ, Gupta M, Camoretti-Mercado B, Schwartz RJ, Gupta MP. Calcium/calmodulin-dependent protein kinase activates serum response factor transcription activity by its dissociation from histone deacetylase, HDAC4: Implications in cardiac muscle gene regulation during hypertrophy. J Biol Chem 2003; 278: 20047-20058.
42. Kakita T, Hasegawa K, Morimoto T, Kaburagi S, Wada H, Sasayama S. p300 protein as a coactivator of GATA-5 in the transcription of cardiac-restricted atrial natriuretic factor gene. J Biol Chem 1999; 274: 12811-12818.
43. Yoshida Y, Morimoto T, Takaya T, Kawamura T, Sunagawa Y, Wada H, et al. Aldosterone signaling associates with p300/GATA4 transcriptional pathway during hypertrophic responses in cardio-myocytes. Circ J 2010; 74: 156-162.
44. Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: Implications for disease and therapy. Nat Rev Genet 2009; 10: 32-42.
45. Oka S, Ago T, Kitazono T, Zablocki D, Sadoshima J. The role of redox modulation of class II histone deacetylases in mediating pathological cardiac hypertrophy. J Mol Med 2009; 87: 785-791.
46. Backs J, Olson EN. Control of cardiac growth by histone acetylation/deacetylation. Circ Res 2006; 98: 15-24.
47. Takaya T, Kawamura T, Morimoto T, Ono K, Kita T, Shimatsu A, et al. Identification of p300-targeted acetylated residues in GATA-4 during hypertrophic responses in cardiac myocytes. J Biol Chem 2008; 283: 9828-9835.
48. Vo N, Goodman RH. CBP and p300 in transcriptional regulation. J Biol Chem 2001; 276: 13505-13508.
49. Wei JQ, Shehadeh LA, Mitrani JM, Pessanha M, Slepak TI, Webster KA, et al. Quantitative control of adaptive cardiac hypertrophy by acetyltransferase p300. Circulation 2008; 118: 934-946.
50. Poizat C, Puri PL, Bai Y, Kedes L. Phosphorylation-dependent degradation of p300 by doxorubicin-activated p38 mitogen-activated protein kinase in cardiac cells. Mol Cell Biol 2005; 7: 2673-2687.
51. Poizat C, Sartorelli V, Chun G, Kloner RA, Kedes L. Proteasome-mediated degradation of the coactivator p300 impairs cardiac transcription. Mol Cell Biol 2000; 23: 8643-8654.
52. Morimoto T, Fujita M, Kawamura K, Sunagawa Y, Takaya T, Wada H, et al. Myocardial regulation of p300 and p53 by doxorubicin involves ubiquitin pathways. Circ J 2008; 72: 1506-1511.
53. Kawamura T, Hasegawa K, Morimoto T, Iwai-Kanai E, Miyamoto S, Kawase Y, et al. Expression of p300 protects cardiac myocytes from apoptosis in vivo. Biochem Biophys Res Commun 2004; 315: 733-738.
54. Miyamoto S, Kawamura T, Morimoto T, Ono K, Wada H, Kawase Y, et al. Histone acetyltransferase activity of p300 is required for the promotion of left ventricular remodeling after myocardial infarction in adult mice in vivo. Circulation 2006; 113: 679-690.
55. Lau OD, Kundu TK, Soccio RE, Ait-Si-Ali S, Khalil EM, Vassilev A, et al. HATs off: Selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF. Mol Cell 2000; 5: 589-595.
56. Balasubramanyam K, Swaminathan V, Ranganathan A, Kundu TK. Small molecule modulators of histone acetyltransferase p300. J Biol Chem 2003; 278: 19134-19140.
57. Balasubramanyam K, Altaf M, Varier RA, Swaminathan V, Ravindran A, Sadhale PP, et al. Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. J Biol Chem 2004; 279: 33716-33726.
58. Balasubramanyam K, Varier RA, Altaf M, Swaminathan V, Siddappa NB, Ranga U, et al. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltrans-ferase-dependent chromatin transcription. J Biol Chem 2004; 279: 51163-51171.
59. Morimoto T, Sunagawa Y, Kawamura T, Takaya T, Wada H, Nagasawa A, et al. The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. J Clin Invest 2008; 118: 868-878.
60. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008; 14: 4491-4499.
61. Kurd SK, Smith N, VanVoorhees A, Troxel AB, Badmaev V, Seykora JT, et al. Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: A prospective clinical trial. J Am Acad Dermatol 2008; 58: 625-631.
62. Chainani-Wu N, Silverman S Jr, Reingold A, Bostrom A, McCulloch C, Lozada-Nur F, et al. A randomized, placebo-controlled, double-blind clinical trial of curcuminoids in oral lichen planus. Phyto-medicine 2007; 14: 437-446.
63. Hsu CH, Cheng AL. Clinical studies with curcumin. Adv Exp Med Biol 2007; 595: 471-480.
64. Johnson JJ, Mukhtar H. Curcumin for chemoprevention of colon cancer. Cancer Lett 2007; 255: 170-181.
65. Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL. A potential role of the curry spice curcumin in Alzheimer's disease. Curr Alzheimer Res 2005; 2: 131-136.
66. Rasyid A, Rahman AR, Jaalam K, Lelo A. Effect of different cur-cumin dosages on human gall bladder. Asia Pac J Clin Nutr 2002; 11: 314-318.
67. Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, et al. Curcumin maintenance therapy for ulcerative colitis: Randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006; 4: 1502-1506.
68. Downey JM, Cohen MV. Why do we still not have cardioprotective drugs? Circ J 2009; 73: 1171-1177.
69. Nakaya H. Does anti-inflammatory action of amiodarone explain the high efficacy in patients with heart failure? Circ J 2009; 73: 622-623.